Drug intelligence / Profile preview

R-IMPP

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intraperitoneal

Overview

R-IMPP is a small molecule inhibitor that targets the 80S ribosome to inhibit the translation of PCSK9, a protein involved in lipid metabolism. It increases LDL receptor levels, thereby enhancing LDL cholesterol uptake in hepatoma cells. R-IMPP has potential therapeutic applications in managing cholesterol levels but is not yet approved for clinical use[3][5][12].

Targets

80S ribosome (Ribosome and ribosomal components)

Beyond the preview

Go deeper on R-IMPP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R-IMPP.

Explore the full profile